• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

URGO Medical Strengthens Its Position in North America by Acquiring Realm Therapeutics’ Assets

Share:

April 15, 2019

URGO Medical, a global leader in wound care, announces the signature of an asset purchase agreement with REALM Therapeutics, owner of Vashe technology. This acquisition reinforces URGO Medical’s innovative product portfolio and its footprint in North America.

URGO Medical acquires a worldwide proprietary innovative technology to strengthen position on North American market

URGO Medical’s activities are dedicated to products that offer relief to patients who suffer from severe wounds, thanks to its portfolio optimized solutions and protocols for healthcare professionals. Following the merger with SteadMed Medical LLC in September 2018 and the creation of URGO Medical North America, this new acquisition confirms URGO Medical ambitions to become a global leading player in the world’s largest advanced wound care market of North America.

“Following the successful integration of Steadmed team and the creation of URGO Medical North America, this acquisition enables us to control the sourcing of Vashe and creates new growth opportunities,” said Laurent Faugère, URGO Medical CEO.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“This acquisition shows the commitment of URGO board to invest in URGO Medical North America to accelerate our growth,” added Michael Steadman, URGO Medical North America CEO

Realm Therapeutics Inc is a US company based in Malvern (near Philadelphia, Pennsylvania) founded in 2006. The company conducts research activities to find new hypochlorous acid based treatments for allergic conjunctivitis and for atopic dermatitis, and commercializes the use of its patents.

The perimeter of this acquisition corresponds mainly to the Intellectual Property (“IP”) – patents and know-how – that the Company has successfully developed and valued over the years.

More specifically, Realm is behind the formulation of Vashe® Wound Solution which is commercialized by URGO Medical North America (formerly Steadmed Medical) since 2013.

By acquiring a worldwide proprietary innovative technology, URGO Medical North America secures and strengthens its innovative woundcare portfolio.

A recognized solution to clean patient wounds

Vashe® Wound Solution is a hypochlorous acid wound cleansing solution which represents a non-antibiotic, non-irritating, non-cytotoxic alternative wound treatment. Sold under prescription this solution is used for cleansing, irrigating, moistening, debridement and removal of foreign material (including microorganism) on acute and chronic dermal lesions (such as stage I-IV pressure ulcers, venous insufficiency ulcers, diabetic ulcers, post-surgical wounds, first and second-degree burns, abrasions and minor irritations of the skin).

Available in the US, Canada, Mexico, Middle East and Chile, Vashe®achieved a 40% growth in 2018.

Date: April 15, 2019

Source: Cision

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Ancestry Launches Consumer Genetics Tests for Health, Intensifying Rivalry with 23andMeAncestry Launches Consumer Genetics Tests for Health, Intensifying Rivalry with 23andMe
  • Microsoft, Astrazeneca Launches AI Factory For Health Accelerator In EuropeMicrosoft, Astrazeneca Launches AI Factory For Health Accelerator In Europe
  • The Pursuit of a 10X Better Value-Based Care Enablement Solution and the Rise of Primary Care Physician Management PlatformsThe Pursuit of a 10X Better Value-Based Care Enablement Solution and the Rise of Primary Care Physician Management Platforms
  • GE to Spin Off Healthcare Unit in Early 2023GE to Spin Off Healthcare Unit in Early 2023
  • Austrian Startup Hi.Health Launches Health Expense Account in EuropeAustrian Startup Hi.Health Launches Health Expense Account in Europe
  • Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals.Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals.
  • Major Depressive Disorder Pipeline Insight Report 2021: Comprehensive Insights About 200+ Companies and 200+ Pipeline DrugsMajor Depressive Disorder Pipeline Insight Report 2021: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs
  • Lilly Completes Acquisition of Loxo OncologyLilly Completes Acquisition of Loxo Oncology

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications